Page last updated: 2024-08-23

plicamycin and lbw242

plicamycin has been researched along with lbw242 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Belka, C; Daniel, PT; Essmann, F; Gillissen, B; Hemmati, PG; Overkamp, T; Preissner, R; Richter, A1

Other Studies

1 other study(ies) available for plicamycin and lbw242

ArticleYear
Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode.
    Cell death & disease, 2013, May-23, Volume: 4

    Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma; Caspase 3; Caspase 8; Colonic Neoplasms; Drug Resistance, Neoplasm; HCT116 Cells; Humans; Oligopeptides; Plicamycin; Proteasome Endopeptidase Complex; RNA Interference; RNA, Small Interfering; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein

2013